Key result
Impella proves safe and potentially superior to IABP, TandemHeart, and ECMO in cardiogenic shock.
Impella is a safe and potentially superior percutaneous mechanical support device for patients with cardiogenic shock.
Supports Impella in cardiogenic shock with caution; leaves open superiority pending randomized trials.
INTRODUCTION: Cardiogenic shock (CS) is a life-threatening condition associated with significant morbidity and mortality. The Impella (Abiomed Inc.) is an axial flow pump on a pigtail catheter that is placed across the aortic valve to unload the left ventricle by delivering non-pulsatile blood flow to the ascending aorta. It is used for high-risk percutaneous coronary intervention and CS. AREAS COVERED: Percutaneous mechanical support devices are placed in a minimally invasive manner and provide life-saving assistance. We review Impella and other percutaneous devices such as intra-aortic balloon pump, TandemHeart, and extracorporeal membrane oxygenation (ECMO) and the evidence supporting their use in the setting of CS. EXPERT COMMENTARY: Impella has been proven to be safe and may be superior to other mechanical support devices in CS.
No takes yet. Share an insight, caveat, or question.
Chera et al. (2018) conducted a review in Cardiogenic shock. Impella vs. Other mechanical support devices (intra-aortic balloon pump, TandemHeart, ECMO) was evaluated. Impella has been proven to be safe and may be superior to other mechanical support devices such as intra-aortic balloon pump, TandemHeart, and ECMO in the setting of cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: